Latest News

According to extended follow-up results from the DeLLphi-300 trial, tarlatamab sustained clinical benefit among previously treated patients with small cell lung cancer.

According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...

According to results from the phase 3 LITESPARK-005 trial, belzutifan significantly improved progression-free survival and overall response among patients with advanced clear-cell renal cell carcinoma, previously treated with immune...

According to phase 1/2 results from the AUGMENT study, revumenib, an inhibitor of the menin-lysine methyltransferase 2A interaction, demonstrated high remission rates with a predictable safety profile among patients with relapsed/refractory...

Sovleplenib, a novel spleen tyrosine kinase inhibitor, demonstrated a clinically meaningful, sustained platelet response among patients with chronic primary immune thrombocytopenia, according to results from a phase 3 study.

According to results from a univariable and multivariable analysis, undergoing lymph node dissection at the time of hysterectomy improved overall survival among patients with stage 3 endometrial cancer.

According to a review of audiometric data, the rate of hearing loss among patients with neurofibromatosis type 1 (NF1) compared to the general population was higher than expected.

Study data shows that a poor prognosis following treatment of frontline venetoclax and hypomethylating agents was demonstrated among a subset of patients with newly diagnosed acute myeloid leukemia with a monocytic immunophenotype.

According to a study, a detection benefit was shown in next-generation sequencing monitoring of measurable residual disease as related to potential for relapse for patients with acute myeloid leukemia after alloHCT, which supports monthly...

According to results from a phase 2/3 study, bevacizumab-erlotinib switch maintenance improved progression-free survival among patients with chemotherapy-responsive advanced biliary tract cancers.